Drug Profile
Grass pollen-derived allergy immunotherapeutic - DMS Imaging
Alternative Names: ABT-011; gp-ASIT+™; gpASIT+; Grass-pollen-allergy-immunotherapy-DMS Imaging; Grass-pollen-allergy-vaccine-DMS Imaging; Grass-pollen-extract-DMS Imaging; Oral-grass-pollen-allergy-vaccine-DMS ImagingLatest Information Update: 29 Jun 2022
Price :
$50
*
At a glance
- Originator BioTech Tools
- Developer DMS Imaging
- Class Allergens; Allergy immunotherapies; Antiallergics; Peptides; Plant allergy immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Allergic rhinoconjunctivitis
Highest Development Phases
- Discontinued Allergic rhinoconjunctivitis
Most Recent Events
- 31 Jan 2021 Discontinued - Phase-II for Allergic rhinoconjunctivitis in Luxembourg, Belgium, France (PO) before January 2021
- 31 Jan 2021 Discontinued - Phase-III for Allergic rhinoconjunctivitis in Czech Republic, Spain, France, Germany, Italy, Hungary, Poland, Belgium (SC) before January 2021
- 17 Oct 2019 Adverse events and efficacy data from phase III trial in Allergic rhinoconjunctivitis presented in the Journal of Allergy and Clinical Immunology (JACI-2019)